Insurers’ decisions about which services to cover are often based on economic models that are seemingly objective but neglect factors affecting people who are economically disadvantaged.
AMA J Ethics. 2021; 23(8):E648-652. doi:
10.1001/amajethics.2021.648.
Elina E. Pliakos and Dr Ankur Pandya join Ethics Talk to discuss how economic decision modeling and value analyses can help reduce waste in health care spending and improve patient care.
Dr Paul T. Menzel joins Ethics Talk to discuss his article: "How Should Willingness-to-Pay Values of Quality-Adjusted Life-Years Be Updated and According to Whom?"
Beatrice L. Brown joins Ethics Talk to discuss her article, coauthored with Dr Aaron S Kesselheim: "How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?"
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019; 21(10):E844-851. doi:
10.1001/amajethics.2019.844.